RxDoctor Payments Data

Bilal Choudry, MD

Neurology · Carlsbad, CANPI 1396921144

Payments from drug & device makers

$277,898in general payments, 2019–2025

Across 2,133 payments — averaging $130.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$76K
  • UCB, Inc.$69K
  • SK Life Science, Inc.$46K
  • Jazz Pharmaceuticals Inc.$37K
  • Livanova USA, Inc.$11K
  • Eisai Inc.$10K
  • plus $30K from 54 others

What the payments were for

  • Consulting fees$15,2956%
  • Speaking & faculty fees$201,09074%
  • Travel & lodging$14,2495%
  • Food & beverage$40,40615%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)462$75,620
UCB, Inc.346$68,841
SK Life Science, Inc.277$45,868
Jazz Pharmaceuticals Inc.73$36,735
Livanova USA, Inc.68$11,177
Eisai Inc.59$9,794
Aquestive Therapeutics, Inc.28$7,320
UCB SA3$6,848
Sunovion Pharmaceuticals Inc.124$3,874
Pfizer94$1,225
Teva Pharmaceuticals USA, Inc.65$1,220
Neurelis, Inc.64$1,055
Lilly USA, LLC46$787
Novartis55$699
Amgen32$642
Neurocrine Biosciences, Inc.24$480
Biohaven Pharmaceutical Holding Company Ltd.43$455
Lundbeck LLC28$451
Biohaven Pharmaceuticals, Inc.23$405
Sumitomo Pharma America, Inc.23$390
Greenwich Biosciences, Inc.12$376
Acadia Pharmaceuticals Inc18$363
Avanir Pharmaceuticals, Inc.27$333
Upsher-smith Laboratories LLC14$269
Impel Pharmaceuticals Inc.11$232
Amneal Pharmaceuticals LLC11$212
Neuropace, Inc.7$191
Merz Pharmaceuticals, LLC8$183
MDD US Operations, LLC6$175
Axsome Therapeutics, Inc.4$155
Biogen7$148
Takeda Pharmaceuticals U.S.A., Inc.1$99
Supernus Pharmaceuticals, Inc.5$85
Sanofi5$81
Kyowa Kirin, Inc.4$80
Assertio Therapeutics, Inc.5$79
Johnson & Johnson3$77
Catalyst Pharmaceuticals, Inc.3$73
Adamas Pharmaceuticals, Inc.4$66
CSL Behring3$54
Promius Pharma LLC3$51
Medtronic(2 entities)2$44
Arbor Pharmaceuticals, Inc.3$43
Aucta Pharmaceuticals, Inc.4$39
Alnylam Pharmaceuticals Inc.2$39
Impel Pharmaceuticals LLC2$38
Bausch Health US, LLC2$37
Acorda Therapeutics, Inc2$34
EMD Serono, Inc.1$33
Ipsen Biopharmaceuticals, Inc1$32
Boston Scientific2$30
Merz North America, Inc.1$25
AstraZeneca1$24
Ceribell, Inc.1$24
Grifols USA, LLC1$22
Scilex Pharmaceuticals Inc.1$21
Immedica Pharma US, Inc.1$21
Microtransponder, Inc.1$19
Aprecia Pharmaceuticals, LLC1$16
Mallinckrodt Enterprises LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,898 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$449,859
Medicare patients
555
Services billed
43,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)77$555,191
BriviactBrivaracetam346$511,281
AptiomEslicarbazepine Acetate178$372,407
XcopriCenobamate106$147,877
VimpatLacosamide78$104,345
BanzelRufinamide18$104,167
Nurtec OdtRimegepant Sulfate49$85,851
BotoxOnabotulinumtoxina38$46,180
QuliptaAtogepant36$44,036
UbrelvyUbrogepant32$40,310
KeppraLevetiracetam13$38,701
Lacosamide318$36,772
Levetiracetam513$25,772
Lamotrigine ErLamotrigine88$22,382
Emgality PenGalcanezumab-Gnlm29$21,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$68,841$633,444446 claims
Sunovion Pharmaceuticals Inc.Aptiom$3,874$372,407178 claims
SK Life Science, Inc.Xcopri$45,868$147,877106 claims
AbbVieBotox, Qulipta, Ubrelvy$75,620$130,526106 claims
Eisai Inc.Banzel, Fycompa$9,794$118,48533 claims
PfizerNurtec Odt, Dilantin$1,225$91,48670 claims
UCB SAKeppra$6,848$38,70113 claims
Aquestive Therapeutics, Inc.Sympazan$7,320$11,74411 claims
Upsher-smith Laboratories LLCTopiramate$269$1,04687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →